These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 12415808)

  • 21. [Development of a new tubulin-interacting agent, docetaxel (taxotere) in Japan].
    Tsukagoshi S
    Gan To Kagaku Ryoho; 1997 Jul; 24(9):1167-74. PubMed ID: 9239173
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Docetaxel in the management of advanced non-small cell lung cancer.
    Miller VA
    Semin Oncol; 1998 Jun; 25(3 Suppl 8):15-9. PubMed ID: 9704671
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Phase II study].
    Niitani H
    Gan To Kagaku Ryoho; 1995 Apr; 22(5):607-10. PubMed ID: 7717711
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Chemotherapy of solid tumors: pharmacologic activity or effectiveness?].
    Longo F; Mansueto G
    Tumori; 1999; 85(6):A26-33. PubMed ID: 10774584
    [No Abstract]   [Full Text] [Related]  

  • 25. Docetaxel: today's results and tomorrow's promises.
    Hortobagyi GN
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):11-4. PubMed ID: 9364535
    [No Abstract]   [Full Text] [Related]  

  • 26. Docetaxel for previously treated non-small-cell lung cancer.
    Fossella FV
    Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):45-51. PubMed ID: 12108897
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overview of docetaxel (Taxotere) in the treatment of non-small cell lung cancer.
    Fossella FV
    Semin Oncol; 1999 Jun; 26(3 Suppl 11):4-8. PubMed ID: 10458203
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long term results of CHART and weekly Paclitaxel in locally advanced non-small cell lung cancer.
    Oral EN
    Lung Cancer; 2005 Sep; 49(3):421-2. PubMed ID: 16102609
    [No Abstract]   [Full Text] [Related]  

  • 29. Combined modality therapy in non-small cell lung and esophageal cancer: a phase I dose-escalation study of docetaxel with concurrent radiotherapy.
    Vokes EE; Mauer AM; Hoffman PC; Haraf DJ
    Semin Oncol; 1998 Jun; 25(3 Suppl 8):28-32. PubMed ID: 9704674
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Taxol in bronchial carcinoma].
    Gatzemeier U
    Med Klin (Munich); 1996 Dec; 91 Suppl 2():1-6. PubMed ID: 9082171
    [No Abstract]   [Full Text] [Related]  

  • 31. Clinical studies of docetaxel (Taxotere) and concomitant chest therapy.
    Vokes EE; Masters GA; Mauer AM; Haraf DJ; Hoffman PC; Golomb HM
    Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-26-S14-29. PubMed ID: 9335521
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The development of docetaxel (Taxotere) in non-small cell lung cancer--docetaxel in new combinations and new schedules: an overview of ongoing and future developments.
    Donnellan PP; Crown JP
    Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-18-S14-21. PubMed ID: 9335519
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sensitivity of non-small-cell lung cancer cell lines established from patients treated with prolonged infusions of Paclitaxel.
    Fujishita T; Loda M; Turner RE; Gentler M; Kashii T; Breathnach OS; Johnson BE
    Oncology; 2003; 64(4):399-406. PubMed ID: 12759538
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Docetaxel (Taxotere) and neoadjuvant chemotherapy for non-small cell lung cancer.
    Mattson K
    Semin Oncol; 1999 Jun; 26(3 Suppl 10):25-8. PubMed ID: 10437748
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Docetaxel for locally advanced or metastatic non-small-cell lung cancer. Current data and future directions as front-line therapy.
    Khuri FR
    Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):53-62. PubMed ID: 12108898
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Docetaxel combination produces 2-year survival advantage in NSCLC patients.
    Oncology (Williston Park); 2001 Dec; 15(12):1559, 1564. PubMed ID: 11780700
    [No Abstract]   [Full Text] [Related]  

  • 37. [Taxenes: a new hope of clinical oncology in the 90-ies].
    Shparik IV
    Vopr Onkol; 1995; 41(1):7-12. PubMed ID: 7667946
    [No Abstract]   [Full Text] [Related]  

  • 38. New chemotherapeutic agents in non-small-cell lung cancer.
    Feigal EG; Christian M; Cheson B; Grever M; Friedman MA
    Semin Oncol; 1993 Apr; 20(2):185-201. PubMed ID: 7683142
    [No Abstract]   [Full Text] [Related]  

  • 39. [Early phase II study of BMS-181339 (paclitaxel) in patients with non-small cell lung cancer. BMS-181339 Non-Small Cell Lung Cancer Study Group].
    Yoneda S; Nishiwaki Y; Niitani H; Kurita Y; Ariyoshi Y; Ikegami H; Furuse K; Fukuoka M; Kimura I; Hara N; Saijo N
    Gan To Kagaku Ryoho; 1996 May; 23(6):695-701. PubMed ID: 8645020
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Docetaxel in lymphangiosis carcinomatosa].
    Pestalozzi BC
    Schweiz Med Wochenschr; 1997 May; 127(19):839. PubMed ID: 9244987
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.